6533b855fe1ef96bd12b0831
RESEARCH PRODUCT
Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis.
Mario P. ColomboClaudia ChiodoniRosalba SalcedoSilvia PiconeseRossana PorcasiChiara RattiGiorgio TrinchieriSabina SangalettiClaudio Tripodosubject
MaleCancer ResearchStromal cellmedicine.medical_treatmentInflammationmedicine.disease_causeAntibodiesArticleMicemedicineLeukocytesAnimalsHumansReceptors Tumor Necrosis Factor Type IItumor necrosis factor mammary carcinogenesis.Crosses GeneticBone Marrow TransplantationInflammationMice KnockoutOncogenebusiness.industryTumor Necrosis Factor-alphaCancerMammary Neoplasms ExperimentalOncogenesmedicine.diseaseImmunohistochemistryMice Inbred C57BLPlatelet Endothelial Cell Adhesion Molecule-1medicine.anatomical_structureCytokineOncologyReceptors Tumor Necrosis Factor Type IImmunologyTumor necrosis factor alphaFemaleBone marrowmedicine.symptomCarcinogenesisbusinessdescription
Abstract Oncogene activation promotes an intrinsic inflammatory pathway that is crucial for cancer development. Here, we have investigated the actual effect of the inflammatory cytokine tumor necrosis factor (TNF) on the natural history of spontaneous mammary cancer in the HER2/neuT (NeuT) transgenic mouse model. Bone marrow transplantation from TNF knockout mice into NeuT recipients significantly impaired tumor growth, indicating that the source of TNF fostering tumor development was of bone marrow origin. We show that the absence of leukocyte-derived TNF disarranged the tumor vasculature, which lacked pericyte coverage and structural integrity, leading to diffuse vascular hemorrhage and stromal necrosis. In addition, tumor-associated Tie2–expressing monocytes were reduced and cytokine expression skewed from Th2 to Th1 type. Treatment of NeuT mice with anti-TNF antibody partially phenocopied the antitumor effect of TNF-deficient bone marrow cell transplantation, providing a strong preclinical background and rationale for the introduction of TNF antagonists in the treatment of human breast cancer, including basal-like samples for which consolidated targeted therapies do not exist. Cancer Res; 70(20); 7764–75. ©2010 AACR.
year | journal | country | edition | language |
---|---|---|---|---|
2010-01-01 | Cancer research |